Related Experiment Video

Updated: Jul 7, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Antiangiogenic therapy in nonsmall cell lung cancer

Martin Gutierrez1, Giuseppe Giaccone

  • 1Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA.

Current Opinion in Oncology
|February 28, 2008
PubMed
Abstract

Insights

Targeting angiogenesis with bevacizumab improved survival for advanced nonsmall cell lung cancer (NSCLC) patients. Further research into vascular endothelial growth factor receptor inhibitors shows promise for NSCLC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Angiogenesis is crucial for tumor growth and metastasis in nonsmall cell lung cancer (NSCLC).
  • Vascular Endothelial Growth Factor (VEGF) is a key mediator of angiogenesis.
  • Targeted therapies offer a promising approach to improve NSCLC patient outcomes.

Purpose of the Study:

  • To review recent findings on targeting angiogenesis mediators in NSCLC.
  • To summarize current and developing treatment options and molecular targets.
  • To discuss the potential of novel anti-angiogenesis agents in NSCLC.

Main Methods:

  • Review of recent clinical trial data and scientific literature.
  • Analysis of efficacy and safety of anti-angiogenesis therapies.
  • Evaluation of small-molecule tyrosine kinase inhibitors targeting VEGF receptors.

Main Results:

  • Bevacizumab, an anti-VEGF antibody, significantly improved overall and progression-free survival in advanced NSCLC when combined with chemotherapy.
  • Bevacizumab was generally well tolerated, but adverse events like bleeding occurred in some patients, particularly those with squamous cell histology or central tumors.
  • Small-molecule VEGF receptor tyrosine kinase inhibitors demonstrated promise in early-phase NSCLC trials.

Conclusions:

  • Targeting angiogenesis, particularly via VEGF, is a viable strategy for NSCLC treatment.
  • Bevacizumab offers a significant survival benefit in advanced NSCLC.
  • VEGF receptor tyrosine kinase inhibitors represent a promising class of novel agents for NSCLC management.

More Related Videos

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...